Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks

Trial Details

NCT ID
NCT05194397
Phase
PHASE2
Sponsor
Children's Hospital of Philadelphia
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Nicotinamide Riboside
  • Placebo
  • Exercise Intervention
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Memphis, Tennessee, United States|35.14953,-90.04898

Key Eligibility Criteria

  • Males and females, ages 10-30 years at enrollment
  • Able to understand and speak English
  • Diagnosis of leukemia (myeloid, lymphoid), aplastic anemia, bone marrow failure syndrome, or myelodysplastic syndrome requiring allogeneic HCT
  • 6-48 months from allogeneic HCT

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →